| Overview |
| bs-4270R-Cy5.5 |
| CDKN2C Polyclonal Antibody, Cy5.5 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat, Dog, Horse |
| Specifications |
| Cy5.5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human CDKN2C |
| 101-168/168 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 1031 |
| Cytoplasm, Nucleus |
| CDK6 inhibitor p18; CDKN 2C; CDKN 6; CDKN2C; CDKN6; CDN2C_HUMAN; Cyclin dependent inhibitor; Cyclin dependent kinase 4 inhibitor C; Cyclin dependent kinase 6 inhibitor; Cyclin dependent kinase 6 inhibitor p18; Cyclin dependent kinase inhibitor 2C p18 inhibits CDK4; Cyclin dependent kinase inhibitor 2C; Cyclin-dependent kinase 4 inhibitor C; Cyclin-dependent kinase 6 inhibitor; INK4C; OTTHUMP00000046546; p18; p18 inhibits CDK4; p18 INK4C; p18 INK6; p18-INK4C; p18-INK6. |
| p18 INK4C is a specific inhibitor of cdk4 / cdk6 (it interacts strongly with CDK6 and weakly with CDK4), and is expressed during G1 to S transition in the eukaryotic cell division cycle. It is maximally induced as cells enter S phase. Highest expression levels are found in skeletal muscle, but it is also found in the pancreas and heart. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz